a b s t r a c tAgainst the backdrop of the transformation of the German energy system, a new dynamic is emerging between the previously separate economic fields of renewable energy systems, transportation, and information and communication technologies (ICT). The trend towards digitalization and interconnectivity is prompting the formation of new corporate alliances and business ideas. We argue that the increasing interactions between actors in these sectors are evidence of the emergence of a new intersectoral field. Building on concepts from neoinstitutionalism, particularly, the framework of strategic action fields (SAF), we examine the overlaps and dynamics that are arising in an exemplar of what policy makers and planners often refer to as "living labs." With help of this case study we observe the cross-field innovation activities taking place at a particular local site. Our empirical examination draws upon a four-year-long ethnography of an innovation campus in Berlin, the German capital. This case reveals the development of interdependent interests and collaborations between both different industries and between companies and academic institutions. These interconnections are built, in part, by socially skilled actors, who act as border crossers between established fields.

During the last 20 years, science policy-making has taken to evaluation as an instrument for assessing research projects, programmes and even entire research institutes or faculties. This article examines key elements of the evaluation systems in the United Kingdom (Research Assessment Exercise), the Netherlands (Standard Evaluation Protocol) and Germany (Leibniz Association's Evaluation Procedure) and the extent to which evaluations serve as an instrument of organizational development for the scientific bodies being evaluated. Evaluations are often mistrusted -particularly in Germany's public discourse -as a Trojan horse of policy-making infiltrating the science system. However, our findings demonstrate that peer-review based evaluations can be an authoritative source of validation employed by scientific institutes to develop or optimize institutional strategies. Against this backdrop, we conclude with recommendations of how institutional evaluations may be further developed and how processes of organizational transformation can be supported in the research landscape.

No abstract

Eosinophil-associated diseases (EADs) are a range of heterogeneous conditions in which eosinophils are believed to play a critical pathological role. EADs include common illnesses such as eosinophilic asthma and chronic rhinosinusitis and rare conditions such as hypereosinophilic syndromes (HES) and eosinophilic gastrointestinal disorders (EGIDs). EADs are associated with substantial burdens for the patient, including chronic, debilitating symptoms, increased financial burden, decreased health-related quality of life, and the need for repeated visits to multiple different healthcare professionals (HCPs), emergency departments, and/or hospitals. Poor EAD recognition by HCPs often contributes to delayed diagnoses, which further delays patient access to appropriate care and effective treatments, contributing to poor health outcomes. The objective of this charter is to outline key patient rights and expectations with respect to the management of their condition(s) and to set forth an ambitious action plan to improve health outcomes for patients with EADs: (1) people with EADs, their caretakers, HCPs, and the public must have greater awareness and education about EADs; (2) people with EADs must receive a timely, accurate diagnosis; (3) all people with EADs must have access to an appropriate multidisciplinary team, when necessary; and (4) people with EADs must have access to safe and effective treatment options without unnecessary regulatory delays. The principles described in this charter demonstrate the core elements of quality care that people with EADs must receive, and they represent clear steps by which to reduce patient and caregiver burden and improve patient outcomes. We urge HCPs, healthcare systems, and policymakers worldwide to swiftly adopt these principles to ensure patients with EADs have an accurate diagnosis in a timely manner and access to high-level care and treatment in an appropriate setting.